Clinical trials: AD - Alzheimer's Disease
Alzheimer's Disease
Effect of NeuroAD on Alzheimer Patients
Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer for the treatment of Alzheimer patients.
- Trial name
- NCT01825317
- Testing
- NeuroAD
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Neuronix Ltd
Alzheimer Disease
A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease
The purpose of this randomized, double-blind, active-controlled, flexible dosage, multicenter study is to evaluate the effectiveness and safety of galantamine tablet (16-24mg/day) for 16 weeks in the treatment of mild to moderate…
- Trial name
- NCT00645190
- Testing
- Galantamine HBr
- Volunteers
- 215 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Alzheimer Disease
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.
The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with Alzheimer's disease, and…
- Trial name
- NCT00301574
- Testing
- galantamine
- Volunteers
- 398 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00362024
- Testing
- MK0952
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
The Feasibility of Florbetapir Quantitation in Europe
This study will evaluate whether the addition of quantitation as an adjunct to visual interpretations significantly improves the accuracy of Amyvid scan interpretation.
- Trial name
- NCT02107599
- Testing
- Florbetapir (18F)
- Where
- Netherlands
- Volunteers
- 96 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease and Related Dementia, Fall Injury
Fall Detection and Prevention for Memory Care Through Real-time Artificial Intelligence Applied to Video
The purpose of the research is to study a new safety monitoring system developed by SafelyYou to help care for a loved one with dementia. The goal is to provide better support for unwitnessed falls.
- Trial name
- NCT03685240
- Testing
- SafelyYou Fall Prevention System
- Where
- United States
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- SafelyYou
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Alzheimer Disease
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US).
- Trial name
- NCT00916617
- Testing
- bapineuzumab
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00809510
- Testing
- ABT-089
- Where
- 22 sites in United States
- Volunteers
- 63 people
- Sponsor
- Abbott
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer's Disease
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT01549834
- Testing
- ABT-126
- Where
- 43 sites in United States, Canada and 5 more
- Volunteers
- 434 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Alzheimer Disease
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT06881836
- Testing
- ONO-2020
- Where
- 80 sites in United States, Japan
- Volunteers
- 260 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Alzheimer Disease
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance.
- Trial name
- Elevage (NCT03980730)
- Testing
- Azeliragon
- Where
- 33 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- vTv Therapeutics
Alzheimer Disease
ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation
ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD).
- Trial name
- NCT00063310
- Testing
- Leuprolide acetate
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Voyager Pharmaceutical Corporation
Alzheimer's Disease
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky protein in the brain…
- Trial name
- IDENTITY-2 (NCT00762411)
- Testing
- LY450139
- Where
- 91 sites in United States, Brazil and 16 more
- Volunteers
- 1,111 people
- Sponsor
- Eli Lilly and Company
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to compare the effectiveness of an oral formulation of risperidone (an antipsychotic medication) to that of placebo for treating behavioral and psychological signs and symptoms in dementia (BPSSD)…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT00249158
- Testing
- Risperidone
- Volunteers
- 344 people
- Sponsor
- Janssen-Cilag Pty Ltd
Alzheimer's Disease
Florbetapir Calibration to the Centiloid Scale
This study is designed to demonstrate the conversion of florbetapir (18F) Positron Emission Tomography (PET) Standard Uptake Value ratio (SUVr) to Centiloid units.
- Trial name
- NCT02120664
- Testing
- Florbetapir (18F), 11C-PiB
- Where
- 2 sites in United States, Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-2 (NCT00348309)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Donepezil
- Where
- 249 sites in United States, Argentina and 17 more
- Volunteers
- 1,496 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients
The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in patients with Alzheimer's disease compared to placebo (inactive substance).
- Trial name
- NCT00357357
- Testing
- HF0220
- Where
- 10 sites in India, Sweden and 1 more
- Volunteers
- 40 people
- Sponsor
- Hunter-Fleming Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.